HRP20231499T1 - Ex-vivo sustav kulture i metode korištenja istog - Google Patents
Ex-vivo sustav kulture i metode korištenja istog Download PDFInfo
- Publication number
- HRP20231499T1 HRP20231499T1 HRP20231499TT HRP20231499T HRP20231499T1 HR P20231499 T1 HRP20231499 T1 HR P20231499T1 HR P20231499T T HRP20231499T T HR P20231499TT HR P20231499 T HRP20231499 T HR P20231499T HR P20231499 T1 HRP20231499 T1 HR P20231499T1
- Authority
- HR
- Croatia
- Prior art keywords
- tissue
- culture
- drug
- culture system
- culture medium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 18
- 238000011124 ex vivo culture Methods 0.000 title 1
- 210000001519 tissue Anatomy 0.000 claims 22
- 229940079593 drug Drugs 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 16
- 239000001963 growth medium Substances 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000007654 immersion Methods 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- WVKOPZMDOFGFAK-UHFFFAOYSA-N 4-hydroperoxycyclophosphamide Chemical compound OOC1=NP(O)(N(CCCl)CCCl)OCC1 WVKOPZMDOFGFAK-UHFFFAOYSA-N 0.000 claims 1
- 241000167854 Bourreria succulenta Species 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- -1 Navalbine Chemical compound 0.000 claims 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical group [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 235000019693 cherries Nutrition 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229960000572 olaparib Drugs 0.000 claims 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960004390 palbociclib Drugs 0.000 claims 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
- 239000010936 titanium Substances 0.000 claims 1
- 229960004066 trametinib Drugs 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/04—Screening or testing on artificial tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/76—Agarose, agar-agar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2539/00—Supports and/or coatings for cell culture characterised by properties
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Sustainable Development (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
Claims (15)
1. Sustav kulture koji se sastoji od medija kulture i precizno izrezanog režnja tkiva postavljenog na umetak kulture tkiva, pri čemu se navedeni precizno izrezani režanj tkiva održava u visoko oksigeniranoj atmosferi koja sadrži najmanje 60 % i manje od 95 % kisika i pri čemu se navedena kultura rotacijski trese olakšavajući povremeno uranjanje navedenog režnja tkiva u navedeni medij kulture.
2. Sustav kulture prema patentnom zahtjevu 1, pri čemu je navedena kultura u ploči s kulturom tkiva.
3. Sustav kulture prema bilo kojem od patentnih zahtjeva 1-2, koji sadrži lijek.
4. Metoda kultiviranja tkiva, metoda koja uključuje kultiviranje precizno izrezanog režnja tkiva na umetku za kulturu tkiva u mediju kulture u visoko oksigeniranij atmosferi koja sadrži najmanje 60 % i manje od 95 % kisika; i trešnja kulture u rotaciji olakšavajući povremeno uranjanje navedenog režnja tkiva u navedeni medij kulture.
5. Metoda prema patentnom zahtjevu 4, koja nadalje sadrži dodavanje lijeka navedenom mediju kulture.
6. Metoda određivanja učinkovitosti lijeka ili serije lijeka, metoda koja obuhvaća:
(i) kulturu tkiva u skladu s metodom prema patentnom zahtjevu 4;
(i) dodavanje lijeka ili serije lijeka navedenom mediju kulture; i
(iii) određivanje učinka navedenog lijeka ili navedene serije lijeka na navedeno tkivo, pri čemu osjetljivost navedenog tkiva navedenom lijeku ukazuje na učinkovitost navedenog lijeka.
7. Sustav kulture prema bilo kojem od patentnih zahtjeva 1-3 ili metoda prema bilo kojem od patentnih zahtjeva 4-6, pri čemu je navedeno tkivo patološko tkivo.
8. Metoda odabira lijeka za liječenje bolesti kod subjekta kojem je to potrebno, metoda koja obuhvaća:
(i) kulturu patološkog tkiva dobivenog od subjekta prema metodi prema patentnom zahtjevu 4;
(ii) dodavanje lijeka navedenom mediju kulture; i
(iii) određivanje učinka navedenog lijeka na navedeno tkivo, pri čemu osjetljivost navedenog tkiva na navedeni lijek ukazuje učinkovitost navedenog lijeka za liječenje navedene bolesti kod navedenog subjekta.
9. Sustav kulture ili metoda prema bilo kojem od patentnih zahtjeva 7-8, pri čemu je navedeno patološko tkivo kancerogeno tkivo.
10. Sustav kulture ili metoda prema bilo kojem od patentnih zahtjeva 1-8, pri čemu je navedeno tkivo odabrano iz skupine koja se sastoji od jajnika, debelog crijeva, pluća, gušterače, želuca, gastroezofagusa, dojke, jetre, hrskavice i kostiju.
11. Sustav kulture ili metoda prema bilo kojem od patentnih zahtjeva 3 i 5-10, pri čemu je navedeni lijek odabran iz skupine koja se sastoji od 5-Flurouricila (5FU), Oksaliplatina, Irinotekana, Cisplatina, 4-hidroperoksi ciklofosfamida, Docetaksela, Doksorubicina, Navalbina, Gemcitabina, Gefitiniba, Tamoksifena, Olapariba, Trametiniba, Everolimusa i Palbocikliba.
12. Metoda prema bilo kojem od patentnih zahtjeva 4-11, pri čemu se navedena kultura provodi najmanje 4 dana.
13. Sustav kulture ili metoda prema bilo kojem od patentnih zahtjeva 1-12, pri čemu je navedeni režanj u izravnom kontaktu s navedenim umetkom kulture tkiva.
14. Sustav kulture ili metoda prema bilo kojem od patentnih zahtjeva 1-13, pri čemu je navedeni umetak kulture tkiva umetak od titanske rešetke.
15. Sustav kulture ili metoda prema bilo kojem od patentnih zahtjeva 1-14, pri čemu navedena visoko oksigenirana atmosfera sadrži najmanje 70 % kisika.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762481738P | 2017-04-05 | 2017-04-05 | |
PCT/IL2018/050390 WO2018185760A1 (en) | 2017-04-05 | 2018-04-03 | Ex-vivo culture system and methods of using same |
EP18723072.7A EP3607050B1 (en) | 2017-04-05 | 2018-04-03 | Ex-vivo culture system and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231499T1 true HRP20231499T1 (hr) | 2024-03-01 |
Family
ID=62116922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231499TT HRP20231499T1 (hr) | 2017-04-05 | 2018-04-03 | Ex-vivo sustav kulture i metode korištenja istog |
Country Status (14)
Country | Link |
---|---|
US (1) | US11920162B2 (hr) |
EP (2) | EP3607050B1 (hr) |
JP (2) | JP2020516243A (hr) |
CN (1) | CN110678543B (hr) |
AU (1) | AU2018248137B2 (hr) |
BR (1) | BR112019020953A2 (hr) |
CA (1) | CA3058168A1 (hr) |
DK (1) | DK3607050T3 (hr) |
ES (1) | ES2963461T3 (hr) |
FI (1) | FI3607050T3 (hr) |
HR (1) | HRP20231499T1 (hr) |
IL (1) | IL269821B2 (hr) |
SI (1) | SI3607050T1 (hr) |
WO (1) | WO2018185760A1 (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2963461T3 (es) | 2017-04-05 | 2024-03-27 | Yeda Res & Dev | Sistema de cultivo ex vivo y métodos de utilización del mismo |
IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
CN114107168A (zh) * | 2020-08-25 | 2022-03-01 | 中国科学院上海药物研究所 | 抗肺纤维化药物筛选模型的构建方法及由其构建的抗肺纤维化药物筛选模型及其应用 |
EP4271995A1 (en) | 2020-12-31 | 2023-11-08 | Elephas Biosciences Corporation | Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue |
IL309061A (en) | 2021-06-06 | 2024-02-01 | Yeda res & development co ltd | Combined cancer treatment |
IL311158A (en) | 2021-08-30 | 2024-04-01 | Yeda res & development co ltd | Combination therapy including MEK and SRC inhibitors for cancer treatment |
CN116622801A (zh) * | 2023-07-24 | 2023-08-22 | 安泰康生物技术(北京)有限公司 | 一种患者来源超微组织培养药物敏感性检测方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
JPS6158582A (ja) * | 1984-08-29 | 1986-03-25 | Advance Res & Dev Co Ltd | 連続還流細胞培養装置 |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US20030152909A1 (en) * | 1994-11-16 | 2003-08-14 | Mitrani Eduardo N. | In vitro micro-organs, and uses related thereto |
US7345031B2 (en) * | 2000-04-12 | 2008-03-18 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
AU2002217911A1 (en) | 2000-11-28 | 2002-06-11 | Curis, Inc. | Basal cell carcinoma cultures, methods related thereto and their use |
US20090239247A1 (en) * | 2002-12-13 | 2009-09-24 | Harris Adrian L | MN and Hypoxia |
US20060134067A1 (en) * | 2003-02-18 | 2006-06-22 | Maxcyte, Inc. | Loading of cells with antigens by electroporation |
US20050130254A1 (en) | 2003-12-16 | 2005-06-16 | Park Sung-Soo | Drug testing system with bio-artificial liver |
GB0512214D0 (en) * | 2005-06-15 | 2005-07-27 | Capsant Neurotechnologies Ltd | Method |
US9175254B2 (en) * | 2006-07-07 | 2015-11-03 | University Of Miami | Enhanced oxygen cell culture platforms |
ES2624177T3 (es) * | 2006-07-07 | 2017-07-13 | University Of Miami | Plataformas de cultivo celular potenciadas en oxigeno |
EP2198013A1 (en) | 2007-09-11 | 2010-06-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro beating heart model |
CN101712946B (zh) * | 2009-09-27 | 2013-02-27 | 南通大学附属医院 | 构建生殖结节器官培养尿道体外发育模型的方法 |
WO2011109651A2 (en) * | 2010-03-03 | 2011-09-09 | The Johns Hopkins University | Expression vectors for classifying cells as cell cycling or hypoxic and methods of use |
AU2011257970A1 (en) * | 2010-05-28 | 2013-01-10 | Garnet Biotherapeutics, Inc | Compositions and methods of using living and non-living bioactive devices with components derived from self- renewing colony forming cells cultured and expanded in vitro |
WO2012083260A2 (en) | 2010-12-16 | 2012-06-21 | Alt Eckhard U | Methods and apparatus for enhanced recovery of cells and of cell-enriched matrix from tissue samples |
GB201100180D0 (en) * | 2011-01-06 | 2011-02-23 | Capsant Neurotechnologies Ltd | Tumour cell and tissue culture |
AU2012320088C1 (en) | 2011-10-04 | 2016-03-17 | Mitra Rxdx India Private Limited | ECM composition, tumor microenvironment platform and methods thereof |
US20140302491A1 (en) | 2011-10-28 | 2014-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Ex Vivo Culture, Proliferation and Expansion of Primary Tissue Organoids |
GB2504996A (en) * | 2012-08-17 | 2014-02-19 | Univ Keele | Embryonic stem cell culture method |
ES2963461T3 (es) | 2017-04-05 | 2024-03-27 | Yeda Res & Dev | Sistema de cultivo ex vivo y métodos de utilización del mismo |
-
2018
- 2018-04-03 ES ES18723072T patent/ES2963461T3/es active Active
- 2018-04-03 BR BR112019020953A patent/BR112019020953A2/pt unknown
- 2018-04-03 IL IL269821A patent/IL269821B2/en unknown
- 2018-04-03 AU AU2018248137A patent/AU2018248137B2/en active Active
- 2018-04-03 DK DK18723072.7T patent/DK3607050T3/da active
- 2018-04-03 CN CN201880035427.1A patent/CN110678543B/zh active Active
- 2018-04-03 HR HRP20231499TT patent/HRP20231499T1/hr unknown
- 2018-04-03 WO PCT/IL2018/050390 patent/WO2018185760A1/en unknown
- 2018-04-03 JP JP2019554559A patent/JP2020516243A/ja active Pending
- 2018-04-03 FI FIEP18723072.7T patent/FI3607050T3/fi active
- 2018-04-03 US US16/499,333 patent/US11920162B2/en active Active
- 2018-04-03 EP EP18723072.7A patent/EP3607050B1/en active Active
- 2018-04-03 SI SI201831030T patent/SI3607050T1/sl unknown
- 2018-04-03 EP EP23193801.0A patent/EP4317971A3/en active Pending
- 2018-04-03 CA CA3058168A patent/CA3058168A1/en active Pending
-
2022
- 2022-11-17 JP JP2022184484A patent/JP2023022119A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL269821B2 (en) | 2024-02-01 |
CN110678543A (zh) | 2020-01-10 |
SI3607050T1 (sl) | 2024-02-29 |
FI3607050T3 (fi) | 2023-11-20 |
ES2963461T3 (es) | 2024-03-27 |
WO2018185760A1 (en) | 2018-10-11 |
CN110678543B (zh) | 2024-04-09 |
EP4317971A3 (en) | 2024-04-17 |
EP3607050A1 (en) | 2020-02-12 |
DK3607050T3 (da) | 2023-11-13 |
EP3607050B1 (en) | 2023-08-30 |
JP2023022119A (ja) | 2023-02-14 |
US20200224171A1 (en) | 2020-07-16 |
IL269821A (en) | 2019-11-28 |
AU2018248137A1 (en) | 2019-11-21 |
RU2019134857A3 (hr) | 2021-07-15 |
BR112019020953A2 (pt) | 2020-05-05 |
EP4317971A2 (en) | 2024-02-07 |
JP2020516243A (ja) | 2020-06-11 |
AU2018248137B2 (en) | 2024-03-07 |
CA3058168A1 (en) | 2018-10-11 |
US11920162B2 (en) | 2024-03-05 |
RU2019134857A (ru) | 2021-04-30 |
IL269821B1 (en) | 2023-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231499T1 (hr) | Ex-vivo sustav kulture i metode korištenja istog | |
JP2020516243A5 (hr) | ||
Poyarkov et al. | A new cryptic species of the genus Microhyla (Amphibia: Microhylidae) from Langbian Plateau, Vietnam | |
Országhová et al. | Overcoming chemotherapy resistance in germ cell tumors | |
Nakaichi et al. | Maxillofacial rhabdomyosarcoma in the canine maxillofacial area | |
Nilanthi et al. | In vitro induction of octaploid from colchicine-treated tetraploid petiole explants of purple coneflower (Echinacea purpurea L.). | |
Korambayil | Granular cell tumour of the hand | |
CN105596239A (zh) | 一种具有防治口腔癌功能的口腔护理产品 | |
Dahanayake et al. | Induction of polyploids from purple coneflower (Echinacea purpurea L.) through colchicine treatments. | |
Zolotarova et al. | HEMAGGLUTININ ANTIGENIC SITES CHANGES OF PANDEMIC INFLUENZA VIRUSES A (H1N1) PDM09 ISOLATED IN 2009-2017 IN UKRAINE | |
Sogabe et al. | Inducing gemmulation in the freshwater sponge Ephydatia muelleri in culture using theophylline | |
Arangusti et al. | Carmona retusa (Tsaanggubat) roots and stem methanolic extract: anti-angiogenic effect | |
Shafiesoltani et al. | Synergistic Anti-proliferative Effects of Lenalidomide and Dexamethasone on the HT-29 Cell Line Through Apoptotic Genes | |
Savytskyi et al. | Comparison of expenditure of using experimental models of carcinogenesis | |
Arbogast et al. | Chirurgisches Forum 2008 | |
Major | Antispasmodic effect of Ephedra major extract on adrenergic and calcium channels receptors in the rat uterus | |
Zhang | Prognostic evaluation of the tongue carcinoma surgery with preservation of the integrity of mandible and dentition | |
Chris | Rättsskipning i Wändele tingzlag: En genusrättslig undersökning av domböcker från Vendels tingslag åren 1736–1737 med fokus på kvinnors ekonomiska medborgarskap. | |
Shridhar et al. | Outcomes Of Adjuvant Radiation Therapy In Resected Extrahepatic Cholangiocarcinoma: A National Cancer Database Analysis | |
Zhao et al. | Dose Escalation 3-Dimension Radiotherapy Is Effective For Esophageal Squamous Cell Carcinoma-Multicenter Retrospective Analysis | |
Farhoudi et al. | Study of dormancy-breaking of Madder seed (Rubia tinctorum) | |
Nalbat et al. | Network-based in silico modeling for drug repurposing and in vitro validation in hepatocellular carcinoma | |
Zolotarova et al. | XIII IMBG All-Ukrainian Conference of Young Scientists | |
Pyurko et al. | Ecological and physiological specificity of Portulaca oleraceae L. Vegetative organs in conditions of Zaporozhye region | |
Shibukawa et al. | A new species of Metzia (Cypriniformes: Cyprinidae) from Northern Laos |